Oregon Health & Science University

The United States Government As Represented by the Department of Veterans Affairs

University of Kansas

Michael Forte

Paolo Bernardi

Frank John Schoenen

Aaron Nilsen

Michael Cohen

Gail Marracci

Jordan Devereaux

Dennis Bourdette

Sudeshna Roy

Justina Sileikyte

The present invention provides compounds useful as mitochondrial permeability transition pore (mtPTP) inhibitors, the compounds being of Formula (I), or a pharmaceutically acceptable salt thereof wherein Ris selected from the group of H, halogen, and C-Calkyl; and Ris selected from the group of H, CF, and halogen; with the proviso that at least one of Rand Ris halogen or CF.

Second generation inhibitors of mitochondrial permeability transition pore with improved plasma stability

The present technology relates to compounds of any one of Formula I, II, IIa, III, IV, and/or V as described herein and their tautomers and/or pharmaceutically acceptable salts, compositions, and methods of uses thereof.

Small molecule inhibitors of the mitochondrial permeability transition pore (mtPTP)

A method for treating a subject with multiple sclerosis is disclosed herein. In one embodiment, a method is provided for treating a subject with multiple sclerosis that includes administering to the subject a therapeutically effective amount of a cyclosporin compound.

Cyclic undecapeptides and derivatives as multiple sclerosis therapies

Growing community of inventors

Portland, OR, United States of America

Michael Forte